Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs MBG 453 (Primary) ; PDR 001 (Primary) ; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 17 May 2017 Planned End Date changed from 20 Apr 2019 to 5 Jun 2019.
- 17 May 2017 Planned primary completion date changed from 20 Apr 2019 to 5 Jun 2019.